Serna Bio founder and CEO Rabia Khan told In Vivo that today the biopharma industry “does not have the toolkit to find small molecules to target RNA, but small molecules are the modality that most pharma companies understand.”
Serna, formally known as Ladder Therapeutics, aims to use “advanced computational methods like machine learning to improve our understanding of...